---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-055084"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:03:33.514612+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Alnylam board changes: Bonney and Bertozzi resign; Arbuckle appointed director

## Summary
- Mike Bonney and Carolyn Bertozzi resigned from Alnylam board effective Dec 2, 2025; no disagreement with company.
- Bertozzi resigned due to election to Eli Lilly board (eff. Dec 8, 2025); will continue as scientific advisor.
- Stuart Arbuckle (ex-Vertex COO) elected to board, effective Jan 5, 2026; receives $75K annual cash retainer plus stock.
- Board size reduced from 11 to 10 following resignations; Arbuckle serves as Class I director until 2026 annual meeting.
- Arbuckle brings commercial and leadership experience from GSK, Amgen, and Vertex; also serves on Rhythm Pharma board.

## SEC filing metadata
- accession: 0001628280-25-055084
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000162828025055084/0001628280-25-055084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000162828025055084/alny-20251202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-055084
- JSON: https://secwatch.observer/filing/0001628280-25-055084.json
- Plain text: https://secwatch.observer/filing/0001628280-25-055084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.